Nuvalent (NUVL) Stock Forecast & Price Target

Compare

168 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NUVL Analyst Ratings

Strong Buy

14 Buy

0 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Nuvalent

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NUVL Stock 12 Month Forecast

Average Price Target

$142.85

▲(50.73% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Nuvalent in the last 3 months. The average price target is $142.85 with a high forecast of $164.00 and a low forecast of $125.00. The average price target represents a 50.73% change from the last price of $94.77.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"67":"$67","116":"$116","165":"$165","91.5":"$91.5","140.5":"$140.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":164,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$164.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":142.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$142.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$125.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[67,91.5,116,140.5,165],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,101.29,106.11384615384615,110.93769230769232,115.76153846153846,120.58538461538461,125.40923076923077,130.23307692307694,135.05692307692308,139.88076923076923,144.70461538461538,149.52846153846156,154.3523076923077,159.17615384615385,{"y":164,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,101.29,104.48692307692308,107.68384615384616,110.88076923076923,114.0776923076923,117.27461538461539,120.47153846153846,123.66846153846154,126.86538461538461,130.06230769230768,133.25923076923075,136.45615384615382,139.65307692307692,{"y":142.85,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,101.29,103.11384615384615,104.93769230769232,106.76153846153846,108.58538461538463,110.40923076923077,112.23307692307692,114.05692307692308,115.88076923076923,117.70461538461538,119.52846153846154,121.35230769230769,123.17615384615385,{"y":125,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":74.98,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.23,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.18,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.76,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.58,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.59,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.95,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.29,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$164.00

Average Price Target$142.85

Lowest Price Target$125.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

John Newman

Canaccord Genuity

$126

Buy

32.95%

Upside

Reiterated

03/16/26

Nuvalent (NUVL) Gets a Buy from Canaccord Genuity

Anupam Rama

J.P. Morgan

$145→$152

Buy

60.39%

Upside

Reiterated

03/13/26

Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP)

David Dai

UBS

$132→$138

Buy

45.62%

Upside

Reiterated

03/02/26

Nuvalent price target raised to $138 from $132 at UBSNuvalent price target raised to $138 from $132 at UBS

Swayampakula Ramakanth

H.C. Wainwright

$155

Buy

63.55%

Upside

Reiterated

02/27/26

Nuvalent: Buy Rating Backed by Late‑Stage Oncology Pipeline and Upcoming Value‑Driving Milestones

Joshua Schimmer

Cantor Fitzgerald

$135→$140

Buy

47.73%

Upside

Reiterated

02/27/26

Cantor Fitzgerald Remains a Buy on Nuvalent (NUVL)

Gregory Renza

Truist Financial

$140

Buy

47.73%

Upside

Reiterated

02/27/26

Truist Financial Sticks to Their Buy Rating for Nuvalent (NUVL)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$164

Buy

73.05%

Upside

Reiterated

02/27/26

Jefferies Sticks to Their Buy Rating for Nuvalent (NUVL)

Etzer Darout

Barclays

$152

Buy

60.39%

Upside

Reiterated

02/26/26

Barclays Sticks to Their Buy Rating for Nuvalent (NUVL)

Charles Zhu

LifeSci Capital

$142

Buy

49.84%

Upside

Reiterated

02/26/26

Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Tango Therapeutics (TNGX)

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

02/26/26

Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Atai Beckley N.V. (ATAI)

David Nierengarten

Wedbush

$125

Buy

31.90%

Upside

Reiterated

02/26/26

De-Risked Oncology Pipeline and Strong Cash Position Underpin Outperform Rating and $125 Target

Bradley Canino

Guggenheim

$155

Buy

63.55%

Upside

Reiterated

02/26/26

Guggenheim Remains a Buy on Nuvalent (NUVL)

Laura Prendergast

Stifel Nicolaus

$115→$135

Buy

42.45%

Upside

Reiterated

01/13/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Tilray (NASDAQ: TLRY) and Nuvalent (NASDAQ: NUVL)

Christopher Raymond

Raymond James

$98.59→$133

Buy

40.34%

Upside

Reiterated

01/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Disc Medicine (NASDAQ: IRON), Nuvalent (NASDAQ: NUVL) and Roche Holding AG (Other OTC: RHHVF)

Kelsey Goodwin

Piper Sandler

$128

Buy

35.06%

Upside

Reiterated

11/20/25

Piper Sandler Remains a Buy on Nuvalent (NUVL)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

John Newman

Canaccord Genuity

$126

Buy

32.95%

Upside

Reiterated

03/16/26

Nuvalent (NUVL) Gets a Buy from Canaccord Genuity

Anupam Rama

J.P. Morgan

$145→$152

Buy

60.39%

Upside

Reiterated

03/13/26

Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP)

David Dai

UBS

$132→$138

Buy

45.62%

Upside

Reiterated

03/02/26

Nuvalent price target raised to $138 from $132 at UBSNuvalent price target raised to $138 from $132 at UBS

Swayampakula Ramakanth

H.C. Wainwright

$155

Buy

63.55%

Upside

Reiterated

02/27/26

Nuvalent: Buy Rating Backed by Late‑Stage Oncology Pipeline and Upcoming Value‑Driving Milestones

Joshua Schimmer

Cantor Fitzgerald

$135→$140

Buy

47.73%

Upside

Reiterated

02/27/26

Cantor Fitzgerald Remains a Buy on Nuvalent (NUVL)

Gregory Renza

Truist Financial

$140

Buy

47.73%

Upside

Reiterated

02/27/26

Truist Financial Sticks to Their Buy Rating for Nuvalent (NUVL)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$164

Buy

73.05%

Upside

Reiterated

02/27/26

Jefferies Sticks to Their Buy Rating for Nuvalent (NUVL)

Etzer Darout

Barclays

$152

Buy

60.39%

Upside

Reiterated

02/26/26

Barclays Sticks to Their Buy Rating for Nuvalent (NUVL)

Charles Zhu

LifeSci Capital

$142

Buy

49.84%

Upside

Reiterated

02/26/26

Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Tango Therapeutics (TNGX)

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

02/26/26

Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Atai Beckley N.V. (ATAI)

David Nierengarten

Wedbush

$125

Buy

31.90%

Upside

Reiterated

02/26/26

De-Risked Oncology Pipeline and Strong Cash Position Underpin Outperform Rating and $125 Target

Bradley Canino

Guggenheim

$155

Buy

63.55%

Upside

Reiterated

02/26/26

Guggenheim Remains a Buy on Nuvalent (NUVL)

Laura Prendergast

Stifel Nicolaus

$115→$135

Buy

42.45%

Upside

Reiterated

01/13/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Tilray (NASDAQ: TLRY) and Nuvalent (NASDAQ: NUVL)

Christopher Raymond

Raymond James

$98.59→$133

Buy

40.34%

Upside

Reiterated

01/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Disc Medicine (NASDAQ: IRON), Nuvalent (NASDAQ: NUVL) and Roche Holding AG (Other OTC: RHHVF)

Kelsey Goodwin

Piper Sandler

$128

Buy

35.06%

Upside

Reiterated

11/20/25

Piper Sandler Remains a Buy on Nuvalent (NUVL)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nuvalent

3 Months

xxx

Success Rate

10/16 ratings generated profit

Average Return

+6.38%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +6.38% per trade.

1 Year

Charles ZhuLifeSci Capital

Success Rate

12/16 ratings generated profit

Average Return

+22.25%

reiterated a buy rating 24 days ago

Copying Charles Zhu's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +22.25% per trade.

2 Years

xxx

Success Rate

10/11 ratings generated profit

Average Return

+27.13%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +27.13% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NUVL Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NUVL has received 24 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. NUVL average Analyst price target in the past 3 months is 142.85.

Each month's total comprises the sum of three months' worth of ratings.

NUVL Financial Forecast

NUVL Earnings Forecast

Next quarter’s earnings estimate for NUVL is -$1.35 with a range of -$1.60 to -$1.20. The previous quarter’s EPS was -$1.58. NUVL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year NUVL has Performed in-line its overall industry.

No data currently available

NUVL Sales Forecast

Next quarter’s sales forecast for NUVL is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. NUVL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year NUVL has Performed in-line its overall industry.

NUVL Stock Forecast FAQ

What is NUVL’s average 12-month price target, according to analysts?

Based on analyst ratings, Nuvalent’s 12-month average price target is 142.85.

What is NUVL’s upside potential, based on the analysts’ average price target?

Nuvalent has 50.73% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NUVL a Buy, Sell or Hold?

Nuvalent has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.

What is Nuvalent’s price target?

The average price target for Nuvalent is 142.85. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $164.00 ,the lowest forecast is $125.00. The average price target represents 50.73% Increase from the current price of $94.77.

What do analysts say about Nuvalent?

Nuvalent’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of NUVL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Nuvalent (NUVL) Stock Forecast & Price Target

NUVL Analyst Ratings

NUVL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Nuvalent

NUVL Analyst Recommendation Trends

NUVL Financial Forecast

NUVL Earnings Forecast

NUVL Sales Forecast

NUVL Stock Forecast FAQ

Detailed List of Analyst Forecasts